But this is good news. Big news!
Apparently, clinical study results have confirmed that a combination of new melanoma (skin cancer) drugs are helping almost all of the difficult to treat, advanced melanoma patients that try it.
Being a melanoma (not to be confused with my multiple myeloma–a bone marrow cancer) survivor, I was especially interested in these findings.
Official trial results will be shared at this year’s ASCO meetings in Chicago. But here are a few excerpts about what to expect:
By Charles Bankhead, Staff Writer, MedPage Today
…94% to 95% of the patients had stable disease, partial response, or complete response, certainly an impressive record by any assessment,” said Weber, of H. Lee Moffitt Cancer Center in Tampa, Fla.
The combination caused fewer side effects than a BRAF inhibitor alone, Jeffrey S. Weber, MD, said during a press briefing in advance of the American Society of Clinical Oncology meeting, which begins May 31 in Chicago.
These patients took a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.
CLICK-HERE to access the entire article.
I will be in Illinois to cover the ASCO meetings. The news there is strictly traditional, big pharma based. But sometimes chemotherapy works. It would probably work better when combined with complimentary medicine, but you won’t find much of that at ASCO.
Still, it’s my job to cover this type of news. Maybe I can pull-down a job covering alternative/complimentary medicine meetings sometime soon.
I don’t care about labels. I just want something–anything to work!
Feel good and keep smiling! Pat